Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19192881 | 0.85 | KMT2A (0.55) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL6726327 | 0.85 | ATM (0.45) | CA1CA2KMT2AMEN1L3MBTL1 | |
| SCHEMBL491319 | 0.82 | PSIP1 (0.61) | CA1CA2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL4416606 | 0.80 | ALDH1A1 (0.56) | CA1CA2ALDH1A1KMT2AMEN1 | |
| SCHEMBL17263850 | 0.77 | PSIP1 (0.68) | CA1CA2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9615420 | 0.75 | CA1 (0.48) | CA1CA2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9303097 | 0.75 | PNMT (0.44) | CA1CA2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL21241451 | 0.72 | HTR2C (0.36) | ALDH1A1TSHRKMT2AMEN1LMNA | |
| SCHEMBL55285 | 0.71 | CA1 (0.44) | CA1CA2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL10571503 | 0.70 | CA2 (0.55) | CA1CA2ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | CA1 4885/4885CA2 4851/4885ALDH1A1 1488/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | CA1 4885/4885CA2 4851/4885ALDH1A1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.